Taking advantage of the US FDA's decision to grant a breakthrough therapy designation for its lead drug candidate drisapersen in partnership with GlaxoSmithKline, Dutch biotechnology firm Prosensa priced its US initial public offering at $13 per share for gross proceeds of $78 million.
Breakthrough status in hand, Prosensa launches $78m IPO
Taking advantage of the US FDA's decision to grant a breakthrough therapy designation for its lead drug candidate drisapersen in partnership with GlaxoSmithKline, Dutch biotechnology firm Prosensa priced its US initial public offering at $13 per share for gross proceeds of $78 million.
More from Musculoskeletal
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.
• By
The gene therapy for Duchenne muscular dystrophy passed the blockbuster sales threshold in 2024. Analysts said the drug’s overall risk/benefit profile still appears solid.
• By
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.